Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Yazar
Gresty, C.
Hussain, M.
Olmos, D.
Thiery-Vuillemin, A.
Twardowski, P.
Roubaud, G.
ÖZGÜROĞLU, Mustafa
Kang, J.
Burgents, J.
Corcoran, C.
Adelman, C. A.
de Bono, J. S.
Mateo, J.
Fizazi, K.
Saad, F.
Shore, N.
Sandhu, S.
Chi, K. N.
Sartor, O.
Agarwal, N.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/3570
https://doi.org/10.1016/j.annonc.2020.08.870
Koleksiyonlar